Aurora Cannabis' shares plunge 28% in three months as a cautious fiscal 2027 outlook overshadows record medical cannabis growth and global expansion.
ACB frames fiscal 2027 as a reset year as Canadian reimbursement pressure weighs on margins, even as global medical cannabis growth continues.
Many marijuana stock investors have a strong positive outlook on the future of the market. If you've been watching the cannabis sector, then you know how volatile and uncertain trading can be. Yet there have been changes that give more upside to what the future of investing can hold. As cannabis is now a class 3 substance federally, more companies are making shifts in their business to get in line with this new legislation.
| Specialty Retail Industry | Consumer Discretionary Sector | Miguel Martin CEO | XHAN Exchange | CA05156X8504 ISIN |
| CA Country | 1,028 Employees | 11 May 2020 Last Dividend | 20 Feb 2024 Last Split | 11 Jul 2014 IPO Date |
Aurora Cannabis Inc. is a leader in the global cannabis industry, engaging in the production, distribution, and sale of cannabis and its derivatives across Canada and international markets. The company operates through three core segments: Canadian Cannabis, European Cannabis, and Plant Propagation. Its strategies include not only addressing the medical and consumer cannabis markets in Canada but also distributing wholesale medical cannabis throughout the European Union, various international regions such as Australia, the Caribbean, South America, and Israel, and providing supply for propagated vegetables and ornamental plants in North America. Furthermore, Aurora Cannabis extends its presence into the distribution and sale of hemp-derived CBD products. Based in Edmonton, Canada, the company has carved out a competitive position in the global landscape by focusing on diverse product offerings and comprehensive patient counseling and outreach services.
Aurora Cannabis produces a range of consumables including dried cannabis, cannabis oils, and capsules. These products are designed for multiple modes of consumption such as smoking, vaporizing, or ingestion in oil, capsule, or edible form. Each method offers a distinctive experience tailored to consumer and medical patient preferences.
The company's portfolio includes edible cannabis products, extracts, and soft gels. These products provide alternatives for those preferring not to inhale their cannabis, offering a variety of potencies and formulas to suit a diverse client base with specific needs.
Aurora's recreational cannabis products span categories such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products. These offerings fall under brands like Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, enabling Aurora to cater to a broad range of consumer tastes and preferences.
With a focus on patient needs, Aurora offers medical cannabis products under brands such as MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. These products are developed to support patients with specific therapeutic needs, ensuring high quality and efficacy.
Aurora distributes and sells a variety of hemp-derived CBD products, including brands like Reliva and KG7. These products cater to the growing demand for non-psychoactive cannabinoid products, offering benefits without the high associated with THC.
Beyond physical products, Aurora Cannabis extends its services to include patient counseling and outreach. This service demonstrates Aurora's commitment to the well-being of its customers, providing valuable information, support, and guidance on the use of cannabis for medical purposes.